Which is better, BPC-157 or KPV?
The two share the same evidence grade (animal only) and the same regulatory status, and both are prohibited in sport, so neither wins on the criteria that matter most. For intestinal inflammation, KPV has two independent 2008 mouse colitis studies with a defined uptake mechanism (PepT1); for tendon or musculoskeletal injury, BPC-157 has the more relevant rodent data, though mostly from one research group. The choice depends on the problem, and in both cases standard medical care should come first because no human data exist. [1] [2] [3] [4] [5] [6]
How do BPC-157 and KPV compare?
| Dimension | BPC-157 | KPV |
|---|---|---|
| What it is [1] [7] | Synthetic 15 amino acid fragment of a gastric protein (body protection compound). | Synthetic tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-melanocyte stimulating hormone. |
| Proposed mechanism [1] [2] [8] | Growth factor receptor upregulation, nitric oxide system modulation, and VEGFR2 driven angiogenesis in animal and cell models. | Taken into gut epithelial and immune cells by the PepT1 transporter, then inhibits NF-kB and MAP kinase signaling and cytokine release. Works without the MC1 receptor and does not cause pigmentation. |
| Main animal evidence [1] [2] [4] [7] | Rat Achilles tendon transection healed faster with more fibroblast outgrowth and migration; rodent studies report healing of NSAID ulcers, fistulas, and anastomoses. | Oral KPV reduced DSS and TNBS colitis in mice; a second lab found faster recovery, weight regain, and less inflammation in DSS and T cell transfer colitis. |
| Independence of the research base [1] [2] [3] | Mostly a small number of laboratories, largely in Zagreb, with limited independent replication. | Two independent laboratories published consistent mouse colitis results in 2008; the total body of work is small. |
| Human evidence [1] [3] [10] | No controlled human trial. Three small uncontrolled pilot reports from one clinic (knee pain, interstitial cystitis, and intravenous safety) reported benefit or no adverse events but had no comparison group. | No indexed human trial for any indication. |
| Theoretical safety concern [1] [8] | Promotes angiogenesis in animals, so a theoretical concern about growth of existing tumors has been raised (not shown in humans). | Dampens NF-kB driven immune signaling, so a theoretical concern about impaired response to infection has been raised (not shown in humans). |
| FDA and compounding status [5] [6] | Removed from 503A Category 2 on April 15, 2026; PCAC recommended the 503A bulks list in July 2026; no final rule yet. | Removed from 503A Category 2 on April 15, 2026; PCAC recommended the 503A bulks list in July 2026; no final rule yet. |
| Note: Identical status. Neither is FDA approved or eligible for 503B outsourcing. | ||
| WADA status [9] | Prohibited at all times under S0 (non-approved substances). | Prohibited at all times under S0 (non-approved substances). |
| Typical cost [5] | No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price. | No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price. KPV is sold in oral and injectable forms, neither lawfully compounded. |
| Note: Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | BPC-157 | KPV |
|---|---|---|
| Class | Synthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compound | Synthetic tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-melanocyte stimulating hormone (alpha-MSH) |
| What it is | A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a shifting FDA compounding status. | Anti-inflammatory fragment of the hormone alpha-MSH; mouse colitis data, no human trial; recommended for FDA's compounding list in July 2026, rule pending. |
| Evidence | Evidence: Animal-only evidence | Evidence: Animal-only evidence |
| FDA status | Regulatory: Under FDA review | Regulatory: Under FDA review |
| Compounding | Removed from the FDA 503A Category 2 list (substances with significant safety risks) on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding BPC-157 to the 503A bulks list. As of the last verification date FDA has not published a final rule listing it, so state boards and pharmacies vary in whether they will compound it. It is not an FDA approved drug and is not eligible for 503B outsourcing. | Removed from the FDA 503A Category 2 list on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding KPV to the 503A bulks list. As of the last verification date FDA has not published a final rule listing it, so it is not on the 503A bulks list and a 503A pharmacy has no federal basis to compound it from bulk; state boards cannot authorize what federal law does not. It is not an FDA approved drug and is not eligible for 503B outsourcing. Products sold as research chemicals or as dietary supplements are not lawful for human drug use. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection (as sold), Oral capsule (as sold), Intraperitoneal, oral in water, and topical (animal studies) | Oral capsule (as sold), Subcutaneous injection (as sold), Topical cream and nasal spray (as sold), Oral in drinking water and intraperitoneal (mouse studies) |
| Typical cost | No lawful compounded price: BPC-157 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | No lawful compounded price: KPV is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Last verified |
Has BPC-157 been tested directly against KPV?
No published trial has compared BPC-157 and KPV directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do BPC-157 and KPV cost?
| Dimension | BPC-157 | KPV |
|---|---|---|
| Typical cost | No lawful compounded price: BPC-157 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | No lawful compounded price: KPV is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Price detail | BPC-157 price by channel | KPV price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Are BPC-157 and KPV combined?
BPC-157 and KPV are sold together in the premixed blend below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend page covers what is in each product, the evidence for each ingredient, and legal status.
- KLOW: No lawful path.
Frequently asked questions
Which is better for gut inflammation or IBD, BPC-157 or KPV?
Neither has been tested in people with inflammatory bowel disease. KPV has two independent mouse colitis studies showing less inflammation and faster recovery; BPC-157 has rodent data on ulcers, fistulas, and NSAID injury. Approved IBD treatments with human trial data remain the standard. [1] [2] [7]
Does KPV cause tanning like other alpha-MSH peptides?
No. KPV is only the last three amino acids of alpha-MSH, and in mice its anti-inflammatory effect did not depend on the MC1 receptor that drives pigmentation. [2]
Can a pharmacy compound BPC-157 or KPV?
No, not from bulk today. Both were removed from FDA's 503A Category 2 list on April 15, 2026, and PCAC recommended both for the 503A bulks list in July 2026, but that recommendation is advisory. Until FDA publishes a final rule, neither is on the 503A bulks list, so a 503A pharmacy has no federal basis to compound them from bulk, and state boards cannot authorize what federal law does not. [5] [6]
Are BPC-157 and KPV allowed in sport?
No. Both are prohibited at all times under S0 of the WADA Prohibited List as non-approved substances. [9]
Has either one been studied in people?
Not in a controlled trial. KPV has no published human study of any kind. BPC-157 has three small uncontrolled pilot reports from one clinic, none of which tested gut disease. Neither has a human dose finding study, so dose figures circulating online come from animal work or sellers, not from human data. [1] [10]
Conditions studied
From the blog
- BPC-157 for gut health: the animal evidence and the missing human trials
BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008PubMed 18061177, 2008
- [2]Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008PubMed 18092346, 2008
- [3]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
- [4]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
- [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [7]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
- [8]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (Curr Neuropharmacol 2016)PubMed 27138887, 2016
- [9]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [10]McGuire FP et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025PubMed 40789979, 2025
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). BPC-157 vs KPV: evidence, cost, and legality. https://peptideagent.ai/compare/bpc-157-vs-kpv- HTML link
<a href="https://peptideagent.ai/compare/bpc-157-vs-kpv">BPC-157 vs KPV: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.